<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Javelin Pharmaceuticals Inc. | Company News & Executive Profiles - JAV | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Javelin Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="10" found="12" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-363503.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions  Your first question comes from Gary Nachman &#8211; Leerink Swann. Gary Nachman &#8211; Leerink Swann   Marty, on the Dyloject filing, what are you including in the NDA in terms of a rense program?  Could you elaborate a little bit on...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 10 Nov 2009 11:07:08 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/partnership.html"><![CDATA[Partnership]]></category>
		<category domain="http://resources.bnet.com/topic/agency.html"><![CDATA[Agency]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/advertising+%2526+promotion.html"><![CDATA[Advertising & Promotion]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F155480-javelin-pharmaceuticals-inc-q2-2009-earnings-call-transcript%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Javelin Pharmaceuticals, Inc. JAV   Q2 2009 Earnings Call   August 11, 2009 8:30 am ET]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 11 Aug 2009 12:08:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-330535.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions.  We&#8217;ll take our first question from Gary Nachman - Leerink Swann. Gary Nachman - Leerink Swann First question on the Ereska data; Marty, what did you mean that the outcome could change in the future after you examine all aspects of the data,...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 11 Aug 2009 11:08:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/dyloject.html"><![CDATA[Dyloject]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+governance.html"><![CDATA[Corporate Governance]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals: Pain for Pleasure]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F154181-javelin-pharmaceuticals-pain-for-pleasure%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[By guest author Nicholas DeCesare, a highly respected investor and journalist within the biopharma realm.   Take one look at a chart of Javelin Pharmaceuticals JAV over the past six months and you will see a stock that has doubled in price but still sits only around $2.00 per...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 06 Aug 2009 02:20:14 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/michael+catalin+vlaicu.html"><![CDATA[Michael Catalin Vlaicu]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharma's Late-Stage Pipeline Pain]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F126137-javelin-pharma-s-late-stage-pipeline-pain%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: Javelin Pharma JAV is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject injectable diclofenac with Therabel Pharma to market the drug in Europe, where it is...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 16 Mar 2009 06:00:32 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/baxter+international+inc..html"><![CDATA[Baxter International Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BAX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">BAX,JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals, Inc., Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-277965.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator Instructions. We will take our first question from Gary Nachman with Leerink Swann. Gary Nachman - Leerink Swann  Hi, good morning. Marty, first what exactly are you looking for the Dyloject observational study? How long are patients actually being tracked, and do you...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 12 Mar 2009 06:25:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/partnership.html"><![CDATA[Partnership]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-247998.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you. Operator instructions We&#8217;ll go to Edmund Kim with JP Morgan. Edmund Kim &#8211; JP Morgan  Hi, thanks for the additional commentary regarding the Dyloject launch in the UK. I have a few questions. One, the &#8211; NDA filing for Dyloject now appears to...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 10 Nov 2008 08:28:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/j.p.+morgan+chase+%2526+co..html"><![CDATA[J.P. Morgan Chase & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/u.k..html"><![CDATA[U.K.]]></category>
		<category domain="http://resources.bnet.com/topic/safety.html"><![CDATA[Safety]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/real+estate.html"><![CDATA[Real Estate]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/j.p.+morgan+chase+%2526+co..html"><![CDATA[J.P. Morgan Chase & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/u.k..html"><![CDATA[U.K.]]></category>
		<category domain="http://resources.bnet.com/topic/safety.html"><![CDATA[Safety]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/real+estate.html"><![CDATA[Real Estate]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JPM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JPM,JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject&#153; at the 12th World Congress on Pain]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_August_21/ai_n28024848]]></link>
		<description><![CDATA[GLASGOW, Scotland -- Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today presented new and successful secondary endpoint data from a previously announced pivotal Phase 3 study of Dyloject([TM]). At the 12th World Congress on Pain, held in Glasgow, Scotland. Dyloject was launched in...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 21 Aug 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/formulation.html"><![CDATA[formulation]]></category>
		<category domain="http://resources.bnet.com/topic/glasgow.html"><![CDATA[Glasgow]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pivotal+corp..html"><![CDATA[Pivotal Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/scotland.html"><![CDATA[Scotland]]></category>
		<category domain="http://resources.bnet.com/topic/u.k..html"><![CDATA[U.K.]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals Inc Q2 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-224381.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions. We will take our first question from Edmund Kim with JPMorgan. Edmund Kim - JPMorgan Hi, great. Thanks for taking the questions. You talked about 25% penetration among 190 gold accounts. At what percentage, do you start to then shift your attention more toward increasing...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 07 Aug 2008 18:24:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
	<item>
		<title><![CDATA[Javelin Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-226365.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Thank you. Operator Instructions. And we will take our first question from Adam Greene from JPMorgan. Adam Greene - JPMorgan  Thanks. Good morning everyone. Martin Driscoll  Good morning, Adam. Adam Greene - JPMorgan  Marty can you talk about your decision to do...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 29 May 2008 14:31:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/javelin+pharmaceuticals+inc..html"><![CDATA[Javelin Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JAV</category>
		<category domain="tickers">JAV</category>
	</item>
</channel>
</rss>
